Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

Citigroup analyst Joanne Wuensch has upgraded Haemonetics (NYSE: HAE) from a Neutral to a Buy rating. The price target for the stock has been raised from $92 to $123.